| Name | Title | Contact Details |
|---|
Superior Industries is a leading global manufacturer of aluminum wheels for light vehicles, founded in 1957 and based in Southfield, Michigan. The company operates nine manufacturing facilities across North America and Europe, employing around 8,000 people. With over six decades of experience, Superior Industries focuses on innovation in lightweighting and advanced finishing technologies to meet the needs of the automotive market. The company specializes in producing light vehicle aluminum wheels, offering custom finishes and designs. It also has expertise in wheel lightweighting, which enhances fuel efficiency and performance. Superior Industries is publicly traded on the New York Stock Exchange under the ticker SUP and positions itself as a supplier to automotive manufacturers that require high-volume, quality wheel solutions.
You can count on Rushlight Ventures to maximize the value of your intellectual property (IP). Rushlight Ventures is a leading venture studio that specializes in the monetization of defense and dual-use intellectual property created by small and mid-sized businesses conducting federally sponsored research. We are both "IP type" and "monetization path" agnostic. We can pursue value creation from your IP via licenses, asset sales, startups, joint ventures, M&A, or internal business units. We work with IP of all varieties, including products, patents, trade secrets, proprietary relationships, and know-how. At Rushlight Ventures, we provide a range of consulting and support services, including: • Licensing • Asset sales • Joint ventures • Startup and spin-out creation • Commercialization planning and TABA support Companies primarily focused on delivering high-quality research, development, testing, and evaluation services (RDT&E) and other large programs may find it challenging to be equally adept at technology commercialization. Thats why Rushlight Ventures (RLV) originated as a venture studio in 2020 within Cornerstone Research Group (CRG), its sister company and a renowned government contractor for more than 25 years. Soon after forming the venture studio, leadership realized that CRG was not the only company grappling with transition and monetization difficulties, and RLV was spun off as an independent entity in 2021. Today, RLV successfully bridges the gap between RDT&E and commercialization through its seasoned team. RLV staff possess decades of experience in new technology development and commercialization, aerospace and defense RDT&E, new company formation, financing, licensing, and mergers and acquisitions. We have the knowledge and ability to take you from now to wow.
A company dedicated to excellence in the insurance and financial services industries. Through data-driven management and lasting relationships, IH has built a solid foundation capable of taking companies to the next level of performance, profitability, and stability. Our business approach is straightforward. We believe that the power and success behind any business or industry lie within knowledge – knowledge of your products, the direction of your company, and the ongoing execution of a stellar strategic plan. These core assets, coupled with unmatched talent from a thriving corporate culture, are what we believe to be the key ingredients for achieving profitable, steady growth.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.